New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

/PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the...

Related Keywords

China ,United States ,Chinese ,Xia Yu ,Kong Beihua ,Wu Xiaohua ,Department Of Obstetrics ,Chinese Medical Association Gynecological Oncology Branch ,Akeso Inc ,Qilu Hospital Of Shandong University ,Prnewswire Akeso Inc ,National Medical Products Administration ,Drug Administration Of The United States ,Fudan University Cancer Hospital ,Global Strategy ,Cervical Cancer ,Healthy China ,Qilu Hospital ,Shandong University ,Drug Administration ,Drug Evaluation ,சீனா ,ஒன்றுபட்டது மாநிலங்களில் ,சீன ,கிஷிய யூ ,துறை ஆஃப் மகப்பேறியல் ,உலகளாவிய மூலோபாயம் ,ஆரோக்கியமான சீனா ,சாண்டோங் பல்கலைக்கழகம் ,மருந்து மதிப்பீடு ,Takeso ,Nc ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,International Medical Approval ,